Overview of drugs approved by the FDA in 2022
The aim of the work is to conduct a review of medications approved by the FDA in 2022.Materials and methods. In searching for the materials to write this review article, bibliographic databases including PubMed, Google Scholar and e-library.ru were utilized. The search was conducted for the publicat...
Saved in:
| Main Authors: | D. V. Kurkin, E. I. Morkovin, D. A. Bakulin, Yu. V. Gorbunova, Yu. A. Kolosov, M. A. Dzhavakhyan, I. E. Makarenko, R. V. Drai, A. V. Zaborovsky, O. V. Shatalova, A. V. Strygin, V. I. Petrov, A. P. Pleten, A. A. Prokopov, T. Yu. Tatarenko-Kozmina |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Volgograd State Medical University, Pyatigorsk Medical and Pharmaceutical Institute
2023-11-01
|
| Series: | Фармация и фармакология (Пятигорск) |
| Subjects: | |
| Online Access: | https://www.pharmpharm.ru/jour/article/view/1353 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Original drugs approved by the Food and Drug Administration (Center for Drug Evaluation and Research) in 2024
by: D. V. Kurkin, et al.
Published: (2025-07-01) -
Implementation of hazard analysis and critical control points (HACCP) in Indian biopharmaceutical industries: A field study
by: Kritangni Dhiman, et al.
Published: (2025-01-01) -
Physiology and pharmacology of glucagon-like peptide-1 receptor
by: D. V. Kurkin, et al.
Published: (2024-01-01) -
Methodological and regulatory aspects of pharmaceutical development of biological products
by: D. V. Kurkin, et al.
Published: (2024-01-01) -
Physiology, pharmacology and prospects for dipeptidilpeptidase-4 inhibitors use
by: D. V. Kurkin, et al.
Published: (2023-05-01)